About this book:

AbbVie was created in 2013 as a spin‑off from Abbott Laboratories to focus exclusively on research‑driven biopharmaceuticals. Leveraging Abbott’s scientific heritage and global infrastructure, the new company launched with a strong portfolio headlined by the blockbuster immunology drug Humira (adalimumab), which provided immediate financial stability and funded aggressive investment in research and development. From its inception AbbVie pursued a strategy of specialization, concentrating on high‑need therapeutic areas while building a robust pipeline of next‑generation therapies.

The company’s growth was driven by both internal innovation and major acquisitions. In immunology AbbVie extended its success with Humira by developing Skyrizi (risankizumab) and Rinvoq (upadacitinib), targeting different inflammatory pathways. Its entry into oncology was marked by the $21 billion purchase of Pharmacyclics (Imbruvica) and later collaborations and acquisitions such as Venclexta with Genentech and ImmunoGen for antibody‑drug conjugates. Neuroscience and aesthetics were dramatically expanded through the $63 billion acquisition of Allergan, adding Botox, Vraylar, Ubrelvy, Qulipta and other products, while subsequent deals with Cerevel, Aliada and Apogee further strengthened its neuroscience and immunology pipelines. AbbVie also addressed hepatitis C with Mavyret and pursued rare diseases and emerging modalities like gene and cell therapies.

Beyond product development, AbbVie emphasized global expansion, operating in over 170 countries, and maintained manufacturing and supply‑chain excellence to ensure reliable delivery of complex biologics and small‑molecule drugs. The company navigated the biosimilar challenge to Humira through legal settlements, lifecycle management and a diversified “growth platform” that reduced reliance on any single product. AbbVie’s corporate culture blended scientific rigor with biotech agility, emphasizing patient centricity, integrity, collaboration and diversity, while its social responsibility initiatives included patient assistance programs, global health partnerships, STEM education and environmental stewardship. Financially, the firm delivered strong revenue growth, profitability and shareholder returns, guided by disciplined capital allocation and transparent investor relations. Leadership transitioned from Richard A. Gonzalez to Robert A. Michael in 2024, maintaining strategic continuity. Looking ahead, AbbVie aims to sustain leadership by advancing its pipeline in immunology, oncology and neuroscience, embracing AI‑driven drug discovery, pursuing targeted acquisitions and continuing to address global health challenges while upholding ethical and regulatory standards.

What You'll Find Inside:

• AbbVie's strategic separation from Abbott Laboratories in 2013 to become a specialized biopharmaceutical company focused on high-unmet medical needs
• The pivotal role of Humira as AbbVie's foundational blockbuster drug and comprehensive strategies to manage biosimilar competition while building next-generation immunology therapies
• AbbVie's expansion into oncology and neuroscience through transformative acquisitions like Pharmacyclics (Imbruvica) and Allergan (Botox, Vraylar, etc.), creating diversified growth platforms
• The company's robust research and development pipeline as the engine for sustained innovation, including next-generation therapies in immunology, oncology, neuroscience, and emerging modalities like ADCs and gene therapies
• AbbVie's global expansion strategy operating in over 170 countries, with targeted approaches for emerging markets and sophisticated market access initiatives for specialty medicines

Who's It For:

This book is ideal for business professionals, investors, and students interested in pharmaceutical industry case studies, corporate strategy, and innovation management. It will particularly benefit those seeking to understand how a company navigates patent cliffs, pursues strategic acquisitions and partnerships, builds sustainable growth beyond flagship products, and addresses global health challenges while maintaining scientific excellence and ethical standards in a highly competitive biopharmaceutical landscape.